Primary Catalyst Driving Peptide And Oligonucleotide CDMO Market Evolution in 2025: Personalized Medicine Drives Growth In Peptide And Oligonucleotide CDMO Market Driver

What Is the Future Outlook for the Peptide And Oligonucleotide CDMO Market's Size and Growth Rate?
The market size for peptide and oligonucleotide CDMO has seen significant expansion recently. The market is projected to escalate from $2.16 billion in 2024 to $2.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.1%. The historical growth pattern is largely due to an upsurge in the need for therapeutic agents, advancements in synthesis and manufacturing procedures, burgeoning personalized medicine trends, regulatory directives, and heightened attention on antiviral peptides and mRNA vaccines, emphasizing the role of oligonucleotides in vaccine production.

The size of the peptide and oligonucleotide cdmo market is predicted to surge significantly in the upcoming years, reaching a majestic sum of $3.79 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. This anticipated growth in the given time frame can be credited to factors like increasing interest in tailored medication, strides in biotechnology, extended applications, more outsourcing, and the escalating effects of chronic illnesses. The trend forecast for this phase involves elements like individualized treatments, advancements in technology, challenges in quality assurance, international expansion, and heightened collaboration among biotech pharmaceutical firms.

What Are the Key Drivers Behind the Growth of the Peptide And Oligonucleotide CDMO Market?
The surge in personalized medicine utilization is anticipated to spur the expansion of the peptide and oligonucleotide CDMO sectors. Personalized medicine is a healthcare approach that customizes medical treatments to individual traits, encompassing genetics, environment, and lifestyle. The upsurge in personalized medicine can be attributed to numerous factors like breakthroughs in genomic technologies, improved comprehension of disease processes at the molecular level, and the demand for more efficient and targeted treatment options based on patients' genetic makeups and medical backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) have a pivotal role in personalized medicine by creating bespoke therapeutic peptides and oligonucleotides specific to patient requirements. For instance, per the Personalized Medicine Coalition, a UK establishment advocating for personalized medicine use, the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized treatments for patients with rare diseases in February 2024, an increase from 6 in 2022. Hence, the increasing adoption of personalized medicine is bolstering the growth of peptide and oligonucleotide CDMO markets.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Key Market Leaders Are Driving Peptide And Oligonucleotide CDMO Industry Growth?
Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

What Are the Emerging Trends in the Peptide And Oligonucleotide CDMO Industry?
The primary participants in the peptide and oligonucleotide CDMO industry are striving to establish strategic alliances to bolster their service provisions, augment their technological prowess, and extend their market penetration. These alliances in peptide development and manufacturing are essentially cooperative arrangements between two entities concentrating on the creation and production of peptide-based treatments. For example, in May 2023, PolyPeptide Group AG, an American CDMO, forged a partnership with Numaferm GmbH, a biotech firm headquartered in Germany, focused on peptide development and production. The objective of this partnership is to leverage PolyPeptide's cGMP manufacturing capabilities and market penetration, in combination with Numaferm's mastery in sustainable peptide production and biochemical manufacturing platforms. Together, they intend to jointly investigate the development of appropriate peptide candidates with the aim of enhancing the sustainability of peptide-based API production.

What Are the Main Segments in the Peptide And Oligonucleotide CDMO Market?
The peptide and oligonucleotide cdmo market covered in this report is segmented -

1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Geographic Area Leads the Peptide And Oligonucleotide CDMO Market?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Peptide And Oligonucleotide CDMO Global Market Report?

- Market Size Analysis: Analyze the Peptide And Oligonucleotide CDMO Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Peptide And Oligonucleotide CDMO Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Peptide And Oligonucleotide CDMO Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Peptide And Oligonucleotide CDMO Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15892

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.